The importance of dissolution for orally inhaled drug products : pharmaceutical, regulatory, and clinical considerations
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Expert opinion on drug delivery - 20(2023), 8 vom: 09. Juli, Seite 1033-1036 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Somby, Karin [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 02.11.2023 Date Revised 02.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/17425247.2023.2205636 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355824124 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355824124 | ||
| 003 | DE-627 | ||
| 005 | 20231226065150.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/17425247.2023.2205636 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1186.xml |
| 035 | |a (DE-627)NLM355824124 | ||
| 035 | |a (NLM)37078605 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Somby, Karin |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The importance of dissolution for orally inhaled drug products |b pharmaceutical, regulatory, and clinical considerations |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.11.2023 | ||
| 500 | |a Date Revised 02.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a In vitro-in vivo correlation (IVIVC) | |
| 650 | 4 | |a dissolution | |
| 650 | 4 | |a inhalation biopharmaceutics classification system (iBCS) | |
| 650 | 4 | |a physiologically based biopharmaceutics modeling (PBBM) | |
| 650 | 4 | |a respiratory | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 700 | 1 | |a Hingle, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Tomic, Ivana |e verfasserin |4 aut | |
| 700 | 1 | |a Forbes, Ben |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on drug delivery |d 2004 |g 20(2023), 8 vom: 09. Juli, Seite 1033-1036 |w (DE-627)NLM159019028 |x 1744-7593 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2023 |g number:8 |g day:09 |g month:07 |g pages:1033-1036 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/17425247.2023.2205636 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2023 |e 8 |b 09 |c 07 |h 1033-1036 | ||